These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 15893927

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM, Garratt RC, Polikarpov I, Andricopulo AD.
    J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS, Patel MR, Talele TT.
    Bioorg Med Chem; 2008 Apr 01; 16(7):3675-86. PubMed ID: 18299198
    [Abstract] [Full Text] [Related]

  • 7. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
    Castilho MS, Postigo MP, de Paula CB, Montanari CA, Oliva G, Andricopulo AD.
    Bioorg Med Chem; 2006 Jan 15; 14(2):516-27. PubMed ID: 16203153
    [Abstract] [Full Text] [Related]

  • 8. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists.
    Doddareddy MR, Lee YJ, Cho YS, Choi KI, Koh HY, Pae AN.
    Bioorg Med Chem; 2004 Jul 15; 12(14):3815-24. PubMed ID: 15210148
    [Abstract] [Full Text] [Related]

  • 9. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA.
    Org Biomol Chem; 2003 Mar 21; 1(6):908-20. PubMed ID: 12929628
    [Abstract] [Full Text] [Related]

  • 10. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
    Kainuma M, Kasuga J, Hosoda S, Wakabayashi K, Tanatani A, Nagasawa K, Miyachi H, Makishima M, Hashimoto Y.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3213-8. PubMed ID: 16617018
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M, Makishima M, Hashimoto Y, Miyachi H.
    Bioorg Med Chem; 2007 Apr 01; 15(7):2587-600. PubMed ID: 17292610
    [Abstract] [Full Text] [Related]

  • 12. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
    Kaur K, Talele TT.
    J Mol Graph Model; 2008 Nov 01; 27(4):409-20. PubMed ID: 18774323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Studies of cannabinoid-1 receptor antagonists for the treatment of obesity: hologram QSAR model for biarylpyrazolyl oxadiazole ligands.
    Ye M, Dawson MI.
    Bioorg Med Chem Lett; 2009 Jun 15; 19(12):3310-5. PubMed ID: 19427207
    [Abstract] [Full Text] [Related]

  • 15. Hologram QSAR model for the prediction of human oral bioavailability.
    Moda TL, Montanari CA, Andricopulo AD.
    Bioorg Med Chem; 2007 Dec 15; 15(24):7738-45. PubMed ID: 17870541
    [Abstract] [Full Text] [Related]

  • 16. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L.
    Trends Mol Med; 2007 Jul 15; 13(7):298-309. PubMed ID: 17588816
    [Abstract] [Full Text] [Related]

  • 17. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R, Gioiello A, Costantino G, Sadeghpour BM, Rizzo G, Meyer U, Parks DJ, Entrena-Guadix A, Fiorucci S.
    J Med Chem; 2006 Jul 13; 49(14):4208-15. PubMed ID: 16821780
    [Abstract] [Full Text] [Related]

  • 18. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
    Takahashi M, Kanayama T, Yashiro T, Kondo H, Murase T, Hase T, Tokimitsu I, Nishikawa J, Sato R.
    Biochem Biophys Res Commun; 2008 Aug 01; 372(3):395-9. PubMed ID: 18457666
    [Abstract] [Full Text] [Related]

  • 19. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 01; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 20. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
    Deng G, Li W, Shen J, Jiang H, Chen K, Liu H.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5497-502. PubMed ID: 18815030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.